Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01060787 · ClinicalTrials.gov registry record
Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant
A clinical trial, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- 98
- Enrollment target
NCT01060787: Completed study, sponsored by Bausch & Lomb Incorporated.
NCT01060787 is a clinical trial that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 98 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01060787 has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- 98 participants
- Enrollment target
Study Summary
Investigate the impact of the Fluocinolone Acetonide (FA) intravitreal implants
Primary Outcome
Bilateral specular microscopy will be performed and endothelial cell density will be recorded.
Interventions
- PROCEDURE Fluocinolone Acetonide 0.59 mg
- PROCEDURE Fluocinolone Acetonide 2.1 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2016-02-04 |
| Est. Completion | 2019-06-07 |
What the finished NCT01060787 record still lists
NCT01060787 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 98 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Fluocinolone Acetonide 0.59 mg is the first listed.
NCT01060787 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01060787 about?
NCT01060787 is a clinical study titled "Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant". Investigate the impact of the Fluocinolone Acetonide (FA) intravitreal implants
What is the current status of trial NCT01060787?
This trial is currently completed. The enrollment target is 98 participants. The study started on 2016-02-04. Estimated completion is 2019-06-07.
What interventions are being tested in trial NCT01060787?
The interventions under investigation include: Fluocinolone Acetonide 0.59 mg (PROCEDURE), Fluocinolone Acetonide 2.1 mg (PROCEDURE).
Who is sponsoring clinical trial NCT01060787?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI